Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

CJC-1295 (No DAC)

Plain-language summaryIntrigue 65 / 100

CJC-1295 (no DAC) is a modified version of growth hormone releasing hormone. It tells the pituitary to release growth hormone in pulses similar to the natural daily rhythm. The no-DAC version has a short half-life of about 30 minutes, suited for matching natural pulsatile patterns rather than producing a constant elevation. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

40/100

Solid pulsatile GHRH analog with real niche utility but thin direct clinical evidence

Look, CJC-1295 nDAC occupies an interesting but crowded corner of the GH secretagogue space. The four point substitutions are clever molecular design: swapping tyrosine-1 to D-alanine and arginine-15 to glutamine neutralizes the principal DPP-4 cleavage sites, extending the biological half-life of native GHRH from under 10 minutes to roughly 30 minutes. That’s real chemistry solving a real problem. What you get is a GHRH analog that actually has time to work at the receptor before enzymatic degradation renders it inert.

The mechanism is solid. GHRH receptor agonism in pituitary somatotrophs, pulsatile GH release, downstream IGF-1 induction: this is well-characterized biology going back decades. The pulsatile release profile is actually the point of the No DAC version. It mimics physiological GH secretion patterns rather than the sustained plasma levels you get from CJC-1295 with DAC. For researchers studying normal GH axis dynamics or testing combination protocols with GH secretagogues, ipamorelin being the obvious co-target, that distinction matters and the pharmacokinetic rationale is clean.

Here’s the thing though: the evidence base is messier than the compound’s reputation suggests. The ConjuChem Phase 2 program was built around the DAC-modified version, not nDAC. Most of what we know about nDAC in humans is extrapolated from that data or from the broader GHRH literature. There isnt a robust, independently replicated clinical dataset specifically for the No DAC formulation. Preclinical data is multi-lab and reasonable, but the translational arrow is weaker than the vendor materials imply, and that matters when you’re deciding where to focus bench resources.

The differentiation story also gets complicated. There are a lot of ways to push GH secretion: native GHRPs, ghrelin mimetics, ipamorelin, CJC-1295 with DAC, sermorelin. In that landscape, nDAC carves out a real but narrow niche. It’s the cleanest pulsatile GHRH analog for research purposes, more stable than sermorelin, but the DAC version dominates for sustained stimulation, and ipamorelin is the cleaner probe if your question is actually about ghrelin receptor biology. You’re picking nDAC specifically when the pulsatile profile is the thing you need to study.

We think the bench value is genuine for programs studying GHRH receptor pharmacology, pulsatile GH biology, or combination secretagogue synergy. What we dont love is that this is a mature compound in a mature class: the discovery excitement is long past, direct clinical evidence for this specific formulation is thin, and the literature is largely downstream of work done a decade ago. Useful tool. Not a priority target for a program that isnt already working the GH axis.

Novelty

32

Mechanism promise

42

In-category differentiation

42

Evidence quality

40

Translational signal

38

Research bench value

52

Rationale The four-point DPP-4-resistant GHRH analog occupies a legitimate but mature space; the Phase 2 evidence base belongs to the DAC version, not nDAC directly, and the compound class is crowded enough that differentiation scores drag the overall down into the low-40s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic 29-residue analog of growth hormone-releasing hormone

A 29-amino-acid GHRH analog with four point substitutions that confer enzymatic stability against dipeptidyl peptidase 4, the principal degradation pathway for native GHRH.

Abstract

CJC-1295 (No DAC), often abbreviated CJC-1295 nDAC and known in the literature as modified GRF(1-29) or simply Mod-GRF, is a synthetic 29-residue analog of human growth hormone-releasing hormone (GHRH) bearing four point mutations relative to the native sequence (CAS 863288-34-0; molecular weight 3367.94). The substitutions are tyrosine-1 to D-alanine (DPP-4 resistance), alanine-8 to glutamine (improved chemical stability), arginine-15 to glutamine (DPP-4 resistance and stability), and asparagine-27 to leucine (improved hydrophobicity and resistance to deamidation). The result is a GHRH analog with substantially extended biological half-life relative to native GHRH (which has a serum half-life under 10 minutes due to rapid DPP-4 cleavage at the N-terminal tyrosine). CJC-1295 nDAC retains the receptor specificity of native GHRH and stimulates pituitary somatotrophs through the GHRH receptor, producing a pulsatile GH release pattern. The “DAC” suffix in the related compound CJC-1295 with DAC refers to a drug affinity complex (a maleimidopropionic acid linker that covalently attaches to serum albumin) that further extends the half-life from approximately 30 minutes to multiple days; the No DAC version omits the linker and the prolonged albumin binding. The two compounds have different pharmacokinetic profiles and different appropriate use cases. CJC-1295 nDAC was originally developed at ConjuChem, Inc., as the parent platform for the DAC-modified version that progressed to Phase 2 trials. The compound is not approved by any regulatory authority for human or veterinary use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-005Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
KPV

Plain-language summaryIntrigue 66 / 100

KPV is a tiny three-amino-acid peptide derived from the C-terminal end of alpha-MSH (the melanocyte-stimulating hormone). It has anti-inflammatory effects, particularly in the gut, and is being studied for inflammatory bowel disease. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

41/100

A 1990s alpha-MSH fragment with real anti-inflammatory preclinical data but thin human evidence and limited novelty

Look, KPV has a genuinely interesting origin story. Back in the early 1990s, Catania and Lipton were doing structure-activity work on alpha-melanocyte stimulating hormone trying to figure out which part of the peptide was responsible for the anti-inflammatory effects versus the parts driving pigmentation, body temperature changes, and feeding behavior. The C-terminal tripeptide, Lys-Pro-Val, retained a lot of the parent hormone’s inflammatory pharmacology without dragging along those other effects. That’s a clean dissection and it’s still the primary reason researchers reach for KPV today.

The mechanism centers on NF-kappa-B attenuation and reduced cytokine output from activated immune cells. NF-kappa-B modulation is not a novel story in 2025; thats a well-trodden pathway with hundreds of compounds claiming to hit it. What makes KPV somewhat more interesting is the melanocortin receptor angle. The specific MCR subtypes responsible for the tripeptide’s anti-inflammatory activity are not fully characterized, which means theres still a real question to answer there. MC1R and MC3R are in the frame, but the binding pharmacology for this three-residue fragment is genuinely incomplete compared to what we know about the full alpha-MSH sequence. That gap is actually useful for bench investigators who want to probe melanocortin-mediated immunomodulation.

The preclinical evidence covers multiple model types: DSS-induced colitis, acute lung injury, contact dermatitis, hepatic ischemia-reperfusion. That breadth is a point in KPV’s favor compared to single-indication peptides. But the literature is noticeably thinner than BPC-157 or TB-500, and neither of those is exactly overflowing with replicated human data. Preliminary clinical work with topical KPV preparations in ulcerative colitis and inflammatory dermatology has been explored, but there’s no FDA-approved IND and human pharmacokinetic data is sparse. We’re firmly in early-human-signal territory, not confirmed efficacy.

Where KPV earns real credit is bench utility. If your research program involves alpha-MSH biology, colitis models, or melanocortin receptor pharmacology, KPV is a legitimate tool. Its short sequence, commercial availability, and defined origin in the alpha-MSH SAR literature make it easier to work with than full-length hormone fragments. The nomenclature confusion around KPV versus KPV-Asn and other fragment lengths is a real sourcing and verification headache; mass spec confirmation of what you’re actually running is essential.

We think KPV is a solid secondary tool for labs already working in MCR or inflammatory peptide biology, but its not a primary research target for most programs. The novelty largely dried up in the 1990s, the human data is thin, and the anti-inflammatory peptide space is crowded. Worth knowing about; not worth centering a program around.

Novelty

35

Mechanism promise

50

In-category differentiation

40

Evidence quality

38

Translational signal

33

Research bench value

52

Rationale KPV scores modestly because most of its structural-activity story was told by Catania and Lipton thirty years ago, and the human evidence base remains early-stage topical work without an approved IND. The partially uncharacterized melanocortin receptor pharmacology and its utility as a probe for dissecting alpha-MSH biology provide genuine but limited upside.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tripeptide C-terminal fragment of alpha-melanocyte stimulating hormone

A 3-amino-acid tripeptide derived from the C-terminus of alpha-MSH, characterized for anti-inflammatory effects in colitis, dermatitis, and hepatic injury models.

Abstract

KPV (sequence Lys-Pro-Val-OH; CAS 67727-97-3; molecular formula C16H30N4O4; molecular weight 342.43) is a synthetic tripeptide corresponding to residues 11-13 of alpha-melanocyte stimulating hormone (alpha-MSH), the C-terminal fragment that retains anti-inflammatory activity in many of the published preclinical models of acute and chronic inflammation. The tripeptide was originally characterized by Catania and Lipton in the early 1990s as part of a structure-activity relationship study of the alpha-MSH inflammatory pharmacology, with the goal of identifying a small fragment that retained the parent hormone’s anti-inflammatory effects without the pigmentation, body temperature, and feeding-behavior effects mediated by the N-terminal portion of the hormone. KPV reproduced the anti-inflammatory effects of alpha-MSH in rodent models of acute lung injury, dextran sulfate sodium-induced colitis, contact dermatitis, and hepatic ischemia-reperfusion injury. The mechanism involves attenuation of NF-kappa-B activation, reduced pro-inflammatory cytokine production by activated immune cells, and modulation of the melanocortin system through receptors that are not yet fully characterized for the tripeptide fragment. There is no FDA-approved IND for KPV in any indication; preliminary clinical work has explored topical KPV preparations for ulcerative colitis and inflammatory dermatologic conditions. The compound is widely used in research-grade work on inflammation and tissue injury. The principal limitations on the strength of the evidence are the relatively small published literature compared to BPC-157 or TB-500 and the limited human pharmacokinetic data.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-009Open in new tab →

Download PDF →

Acquire KPV from the catalog

View KPV →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
MOTS-c

Plain-language summaryIntrigue 90 / 100

MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA, making it a unique mitochondrial-derived peptide. It activates AMPK, a master metabolic regulator linked to insulin sensitivity, fat oxidation, and exercise capacity. Research interest spans metabolic disease and longevity. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

66/100

First mitochondrial sORF peptide with real AMPK signal and maturing multi-lab preclinical base

Look, when the Lee and Cohen groups at USC published the MOTS-c discovery in 2015, the finding was legitimately surprising. A peptide encoded within the mitochondrial 12S rRNA gene, translated from a short open reading frame on the complementary strand. That’s not how people thought about mitochondrial genetics at the time. The mitochondrial genome was supposed to encode a handful of respiratory chain components plus the rRNA and tRNA scaffolding. Finding a biologically active peptide signal hiding in there was the kind of result that reshapes how investigators think about what mitochondria actually are.

The mechanism is what keeps us interested. MOTS-c activates AMPK, which is a well-worn pathway. But the way it does it, and the upstream biology, is not the typical story. The compound also modulates the methionine and folate cycles, which puts it at an interesting intersection between one-carbon metabolism and energy sensing. Multi-target in a way that opens genuine research questions rather than just adding complexity. The age-related decline in plasma MOTS-c levels in humans provides a rationale for the geroprotective angle thats hard to dismiss, even if it’s correlative.

Preclinical replication is real. This isnt a one-lab story. Multiple independent groups have extended the original USC work into diet-induced obesity models, exercise capacity, bone density, immune function, and aging contexts. For a 2015 discovery, the literature has grown at a solid pace. CohBar, the company that licensed the platform, has moved into Phase 1, which is further along the clinical pipeline than most peptides in this class ever get.

What we don’t love: the human data is essentially not there yet. Plasma-level correlations with aging are suggestive, not mechanistic. Phase 1 tells you almost nothing about efficacy. Until we see Phase 2 data in a real metabolic indication, the translational signal is more promise than proof. The preclinical effect sizes are real, but rodent-to-human translation in metabolic peptides has a well-documented failure rate.

We think the bench value here is high for anyone working on aging biology, mitochondrial signaling, or AMPK pathway research. MOTS-c gives you a clean way to probe mitochondrial-nuclear crosstalk in a way that simple AMPK activators don’t approximate. It’s also the most characterized member of a peptide family where the class-level biology is still being written. That’s useful. If you’re building a research program around metabolic aging or mitochondrial endocrinology, this compound belongs in the toolkit at the preclinical stage.

Novelty

72

Mechanism promise

76

In-category differentiation

72

Evidence quality

55

Translational signal

42

Research bench value

72

Rationale MOTS-c scores on novelty and mechanism because it’s the first characterized sORF peptide from the mitochondrial genome, opening a genuinely new class of endocrine signals. Evidence quality and translational signal are held back by the absence of completed human trials; Phase 1 is initiated by CohBar but no results are published, and the human signal so far is correlative (age-related plasma decline). Bench value is real for investigators working on aging, AMPK biology, or mitochondrial-nuclear crosstalk.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

16-residue mitochondrial-derived peptide, AMPK pathway modulator

A short open reading frame encoded within mitochondrial 12S rRNA, reported to modulate insulin sensitivity, exercise capacity, and metabolic homeostasis through AMPK-dependent mechanisms.

Abstract

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA-c; sequence Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg; CAS 1627580-64-6; molecular formula C100H152N28O22S2; molecular weight 2174.59) is a 16-amino-acid peptide encoded within an open reading frame in the mitochondrial 12S ribosomal RNA gene MT-RNR1, first characterized in 2015 by Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California. It is the first short open reading frame (sORF) peptide identified in the mitochondrial genome, and its discovery has opened a substantial line of work on small mitochondrial-encoded peptides as endocrine and paracrine signals. Reported activities include enhanced insulin sensitivity in diet-induced and genetic obesity models, increased exercise capacity, improved glucose homeostasis through AMP-activated protein kinase (AMPK) activation, attenuated age-related insulin resistance, and effects on bone mineral density and immune function. Plasma MOTS-c levels decline with age in humans, which is the rationale for the geroprotective framing of the compound in research-grade vendor literature. The published preclinical literature is robust and has expanded steadily since 2015 with multiple independent laboratories contributing replication and extension studies. There is no FDA-approved IND for MOTS-c in any indication; preliminary Phase 1 work has been initiated by CohBar, Inc., the company that has licensed the platform from USC. The compound is not approved by any regulatory authority for human or veterinary use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-008Open in new tab →

Download PDF →

Acquire MOTS-c from the catalog

View MOTS-c →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
Selank

Plain-language summaryIntrigue 71 / 100

Selank is a synthetic seven-amino-acid peptide developed in Russia as an analog of the immune peptide tuftsin. It has anxiolytic and immunomodulating effects in research and is approved as a prescription anxiolytic in Russia. It does not produce sedation or dependence. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

42/100

Genuinely interesting neuroimmune probe from Russian development, held back by single-consortium evidence and absent Western replication

Look, Selank is one of those compounds where the backstory is genuinely interesting but the evidence base keeps you from getting too excited. Developed in the early 1990s at the Institute of Molecular Genetics in Moscow, it started as an attempt to stabilize tuftsin, a naturally occurring tetrapeptide cleaved from immunoglobulin G. Tuftsin had documented immunomodulatory effects but fell apart in plasma before doing much useful work. The Russian team appended Pro-Gly-Pro to the C-terminus, and suddenly they had a stable heptapeptide with a more complex pharmacology than the parent compound ever suggested.

The mechanism picture is what makes Selank worth knowing about. It hits GABA-A modulatory pathways, which explains the anxiolytic profile; inhibits enkephalinase, prolonging endogenous opioid peptide activity; and retains tuftsin-like immunomodulatory signaling through its core sequence. Thats three distinct biological axes in one compound, and the neuroimmune overlap is genuinely underexplored in Western labs. The idea that you can modulate anxiety phenotypes and immune tone simultaneously through a single peptide sits at an intersection that very few research tools occupy, and that gives it real probe value.

Here’s the thing, though: the evidence is almost entirely Russian-language. The compound is registered as a prescription medicine for generalized anxiety disorder in the Russian Federation, which is not nothing. It means somebody ran trials and satisfied a regulatory body. But the trials were small, sample sizes modest, and Western independent replication is essentially absent. This is the same structural problem that limits Epitalon and Cerebrolysin: single-consortium dominance, language barrier, and no serious external challenge to the methodology. We dont know whether the registration-level data would survive rigorous peer review at a major Western journal, because it hasnt been subjected to that process.

For a bench investigator working the neuroimmune axis, Selank is one of very few tools that sits specifically at the anxiety-immunity intersection. The enkephalinase inhibition angle in particular is underexplored outside Russia, and thats a legitimate open question. If your lab is studying tuftsin receptor biology, or asking how peripheral immune signals translate into CNS anxiolytic endpoints, Selank has something to offer that you cant easily replicate with a standard benzo or SSRI.

What we dont like: the evidence pyramid is inverted. Clinical registration came largely from the same group that built the compound. The Western preclinical literature is thin. Nobody has seriously challenged the most-cited findings outside the Zakusov-aligned network. Until a multi-lab Western effort produces independent data, Selank stays in the plausible-and-interesting-but-unvalidated bucket. We’d score it meaningfully higher if the Moscow consortium findings had been put under external stress and survived. They havent yet.

Novelty

38

Mechanism promise

50

In-category differentiation

40

Evidence quality

35

Translational signal

42

Research bench value

45

Rationale Selank’s multi-mechanism profile (GABA-A modulation, enkephalinase inhibition, tuftsin-like immunomodulation) is legitimately interesting and earns it above-floor scores on mechanism and bench value, but the evidence base is structurally compromised by near-total reliance on the same Moscow consortium that developed the compound, with minimal Western replication. Russian prescription registration is meaningful but insufficient to move the evidence axis much; this places Selank squarely in single-lab-only territory alongside Epitalon and Cerebrolysin.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic heptapeptide anxiolytic, tuftsin analog

A 7-residue peptide developed at the Russian Academy of Sciences as a stable analog of tuftsin, characterized for anxiolytic, immunomodulatory, and cognitive endpoints in a substantial Russian-language literature.

Abstract

Selank (sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro; CAS 129954-34-3; molecular formula C33H57N11O9; molecular weight 751.85) is a synthetic heptapeptide developed in the early 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the Zakusov Research Institute of Pharmacology. The peptide is a stabilized analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from immunoglobulin G that has documented immunomodulatory effects but a very short half-life. Selank extends the tuftsin sequence with the C-terminal tripeptide Pro-Gly-Pro to confer protection against rapid peptidase degradation. The compound has been studied principally in the Russian clinical and preclinical literature, with the largest body of work on anxiolytic effects in generalized anxiety disorder, immunomodulatory effects in viral and bacterial infection models, and cognitive effects in attention and memory tasks. Selank is registered as a prescription medicine in the Russian Federation for the treatment of generalized anxiety disorder under the trade name Selank Bioregulator. The compound is not approved by any regulatory authority outside the Russian Federation; clinical use in the United States, the European Union, and Japan is off-label and outside the scope of regulatory oversight. The principal limitations on the strength of the evidence are the dominance of the Russian-language literature, limited Western independent replication of the most-cited findings, and the relatively small clinical sample sizes in the published trials.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-010Open in new tab →

Download PDF →

Acquire Selank from the catalog

View Selank →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
GHK-Cu

Plain-language summaryIntrigue 68 / 100

GHK-Cu is a tiny three-amino-acid peptide bound to copper. It is naturally present in human plasma at decreasing levels with age. Research suggests it supports skin healing, hair growth, and tissue regeneration. It is widely used in cosmetic skincare. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

52/100

Reference copper transport peptide with real cosmetic track record but modest novelty and unresolved mechanistic breadth

Look, GHK-Cu has been around since 1973. Pickart isolated it from human plasma as a grad student at UCSF, and in the five decades since it has accumulated what is probably the most multidisciplinary literature base of any small bioactive peptide in serious research circulation. That breadth is real. It’s also part of the problem.

The core mechanism involves copper(II) coordination through the His imidazole nitrogen, the Gly N-terminus, and the Lys side chain, forming a stable picomolar-affinity complex that functions as a copper chaperone at the tissue level. That part is well-characterized. Where it gets complicated is the downstream biology: multiple groups have reported modulation of upward of 4,000 human genes in cultured cells, effects on collagen and elastin synthesis, anti-inflammatory cytokine shifts, hair follicle cycling, and antioxidant pathway induction. We think the copper transport story is the load-bearing mechanism; the gene expression data is interesting but the causal chain linking copper delivery to that breadth of transcriptional change isnt fully worked out. The monograph flags this honestly: effects at one dose or route don’t always translate to another context, and that’s a real limitation on how seriously you can stack the preclinical literature.

Translational signal is strongest in the dermal space. GHK-Cu has genuine cosmetic regulatory approval in multiple jurisdictions as Copper Tripeptide-1, which gives it a legitimate bench-to-market arrow that most research peptides lack entirely. For wound healing and dermal remodeling, the human-relevant signal is real, even if the clinical trial infrastructure is thin by pharma standards. Systemic use is a different story: there’s no FDA IND, the pharmacokinetic data for non-topical routes is heterogeneous, and programs working systemically are largely building on preclinical foundations that weren’t designed for that purpose.

What we like here is the bench utility. If your program involves copper biology, wound repair, or skin extracellular matrix remodeling, GHK-Cu is the reference compound. Thats not a small thing. The age-related decline in plasma GHK-Cu concentrations is a legitimate gerontological question, and the compound is a real probe for investigating those dynamics. The analytical challenge is stoichiometry: vendors don’t always specify which GHK:Cu(II) complex they’re supplying, and the 1:1 complex behaves differently from the 2:1 and 1:2 forms. Sourcing verification matters more here than for most peptides in this class.

Honestly, the novelty story is what it is: this isn’t a frontier compound. The gene expression angle and the longevity hypothesis keep it from being purely historical, but we’re not going to pretend it scores on freshness. What GHK-Cu offers is a well-characterized, multidisciplinary research tool with a real cosmetic regulatory track record and a manageable sourcing landscape, for programs where copper-peptide biology is actually the question being asked.

Novelty

40

Mechanism promise

52

In-category differentiation

58

Evidence quality

55

Translational signal

52

Research bench value

62

Rationale GHK-Cu earns its score through genuine bench utility as the field’s reference copper transport peptide and a real translational signal in dermal applications, offset by modest novelty (discovered 1973), heterogeneous preclinical evidence across dose and route, and a causal chain linking copper delivery to 4,000-plus gene modulation that remains incompletely characterized.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tripeptide-copper(II) complex, copper transport peptide

A naturally occurring tripeptide that binds copper(II) with very high affinity, characterized as a wound healing and tissue remodeling peptide with a substantial multidisciplinary literature.

Abstract

GHK-Cu (sequence Gly-His-Lys complexed with Cu(II); CAS 89030-95-5; molecular formula C14H22N6O4Cu; molecular weight 401.91) is a naturally occurring tripeptide-copper(II) complex first isolated from human plasma in 1973 by Loren Pickart, then a graduate student at the University of California San Francisco. The free tripeptide GHK is present in human plasma at low micromolar concentrations and has very high affinity for Cu(II) (apparent dissociation constant in the picomolar range), forming the GHK-Cu complex that is the active species in many of the published bioassays. The compound has the most multidisciplinary published literature of any of the small bioactive peptides in research-grade circulation, with documented or suggested effects on wound healing, hair follicle activity, dermal collagen and elastin synthesis, anti-inflammatory cytokine modulation, modulation of more than 4,000 human genes (in cultured cells), and antioxidant defense. Plasma GHK-Cu concentrations decline with age, which is the rationale for many of the gerontology-focused claims. GHK is approved as a topical cosmetic ingredient in many jurisdictions and is widely used in dermatologic preparations. There is no FDA-approved IND for systemic GHK-Cu in any indication. The principal limitations on the strength of the evidence are heterogeneity in the dose, route, and formulation of GHK-Cu across the published preclinical literature; effects observed at one dose or route do not always translate to other contexts.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-007Open in new tab →

Download PDF →

Acquire GHK-Cu from the catalog

View GHK-Cu →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
Semax

Plain-language summaryIntrigue 73 / 100

Semax is a synthetic seven-amino-acid peptide derived from a fragment of ACTH (a stress hormone). It is approved in Russia as a nootropic and stroke recovery medication. Research suggests effects on BDNF, dopamine, and other neurotrophic systems. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

42/100

Multi-mechanistic neuropeptide with a genuine mechanism story undermined by a Russian-only evidence base

Look, Semax is one of those compounds where the mechanism story is genuinely more interesting than the evidence base deserves. The Institute of Molecular Genetics built out a real mechanistic rationale over decades: ACTH(4-10) fragment, Pro-Gly-Pro tail to buy it some peptidase protection, a multi-target profile that touches melanocortin receptors, upregulates BDNF and NGF expression, and inhibits enkephalinase. Thats a substantive mechanism, and its not a boring one. Most synthetic nootropic peptides in this class operate on a single receptor or a loosely defined neuroprotection claim. Semax at least has specific, testable downstream biology.

The problem is the literature. Almost everything worth citing comes out of Russian groups, often the same consortium that developed the compound. Western labs have not meaningfully picked up the replication work. The clinical registration in the Russian Federation for ischemic stroke recovery and TIA is meaningful in the sense that someone ran studies and got a regulatory nod, but those studies don’t meet the bar Western reviewers would require: small sample sizes, limited methodological transparency in the published reports, no independent multi-site replication. Its the Cerebrolysin problem repeated: decades of regional literature, real signal, but the epistemic infrastructure that would let a Western investigator trust the effect size simply isn’t there.

What we like about Semax is the BDNF and NGF upregulation angle. As interest in neuroplasticity and neurotrophic factor biology has accelerated in Western research, the documented effects on BDNF expression in rodent ischemia models and cognitive paradigms give it a hook worth taking seriously. The melanocortin receptor pharmacology is also underexplored in the West, and Semax is one of the cleaner available probes for that system without engaging the steroidogenic machinery of full ACTH. If youre building a comparative peptide panel for neuroplasticity work, Semax belongs in the conversation.

We dont think Semax is a bad compound. We think its a compound that Western investigators have simply not touched at scale, and that gap is both a limitation and an opportunity. Lot 20260331 comes in at 99.75 percent HPLC purity, which is solid, and the corrected molecular weight of 813.92 is consistent with the reference literature. Reconstitution and handling are straightforward for a heptapeptide of this profile.

What keeps the score at 42 is straightforward: evidence quality is not replication-grade by Western standards, differentiation within the cognitive peptide space is real but not dominant, and the translational signal is essentially conditional on trusting a regional regulatory record. Semax sits in the tier of compounds that are worth including in a research library and worth using as a tool, but not worth anchoring a program around until someone runs serious independent replication outside the originating consortium.

Novelty

40

Mechanism promise

55

In-category differentiation

38

Evidence quality

35

Translational signal

40

Research bench value

45

Rationale Semax scores well on mechanism diversity, touching melanocortin receptors, upregulating BDNF and NGF, and inhibiting enkephalinase, but the evidence base is dominated by a single regional literature with no meaningful Western replication, placing it alongside Cerebrolysin as a compound with real preclinical signal and deeply uncertain epistemic standing for a Western research program. The clinical registration in Russia is meaningful but doesn’t substitute for independent multi-site trials at Western standards.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic heptapeptide nootropic, ACTH(4-10) analog

A 7-residue peptide derived from ACTH(4-10), developed at the Russian Academy of Sciences and registered for clinical use in stroke recovery and cognitive indications.

Abstract

Semax (sequence Met-Glu-His-Phe-Pro-Gly-Pro; CAS 80714-61-0; molecular formula C37H51N9O10S; molecular weight 813.92) is a synthetic heptapeptide developed in the early 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences. The peptide is a stabilized analog of the N-terminal heptapeptide of adrenocorticotropic hormone (ACTH(4-10)), a fragment that retains many of the cognitive and neuroprotective effects of the parent hormone without the steroidogenic effects mediated by the C-terminal portion. Semax extends the ACTH(4-10) sequence with the C-terminal tripeptide Pro-Gly-Pro (the same stabilizing extension used in Selank) to confer protection against rapid peptidase degradation. The compound is registered as a prescription medicine in the Russian Federation for ischemic stroke recovery, transient ischemic attack, and several other neurological and cognitive indications. The published preclinical and clinical record includes work on neuroprotection in cerebral ischemia models, modulation of BDNF and NGF expression, melanocortin receptor signaling effects, and cognitive enhancement endpoints. The compound is not approved by any regulatory authority outside the Russian Federation. The principal limitations on the strength of the evidence are the dominance of the Russian-language literature, limited Western independent replication of the most-cited findings, and the relatively small clinical sample sizes by Western regulatory standards. The lot of record at Kodiac biolabs (lot 20260331) carries a vendor-reported HPLC purity of 99.75 percent.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-011Open in new tab →

Download PDF →

Acquire Semax from the catalog

View Semax →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
9-Me-BC

Plain-language summaryIntrigue 64 / 100

9-Me-BC (9-methyl-beta-carboline) is a small molecule based on the beta-carboline scaffold. Research suggests it has dopaminergic neuroprotective effects, with potential implications in Parkinson disease research. Capsule format here. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

44/100

Genuine dopaminergic neuroprotective signal, but single-consortium evidence and zero human data cap the research priority

Look, the mechanism story here is genuinely worth reading. 9-Me-BC sits inside the beta-carboline family but the 9-position methylation does something important: it substantially reduces MAO-A affinity relative to harmine or harmaline and strips away most of the psychoactive profile those relatives carry. What you get instead is a compound characterized for dopaminergic neuroprotective effects, increased dopamine neuron differentiation in cell culture, and elevated BDNF expression in rodent brain tissue. For anyone running experiments on dopaminergic system maintenance or neurotrophic factor dynamics, that combination is a real signal worth paying attention to.

The differentiation angle matters for experimental design. If youre trying to probe dopaminergic neuroprotection without MAO-A pharmacology confounding your readout, 9-Me-BC carves out a reasonably clean space. The 182 Da molecular weight and reported oral bioavailability make it easier to work with than peptide-based approaches to adjacent questions. The BDNF connection adds a second axis that could be useful for designs crossing dopaminergic and neurotrophic factor biology.

Here’s the thing though: when you actually audit where the evidence comes from, the limitations are serious. The research record dates to the 2010s and is dominated by a small cluster of German neuroscience labs. Thats not a fatal problem on its own, but there is no independent multi-lab replication that would let you trust the effect sizes, and there is no human clinical data at all. Not preliminary phase 1 work, not small-N observational, nothing. So you have an interesting mechanism and rodent plus cell culture data from a single research community, and the translational arrow is pointing at a question mark.

We’ve seen this pattern before. The BPC-157 literature has the same structural problem, and the credibility of that body of work has aged in ways that should make any serious investigator cautious about single-consortium signals. 9-Me-BC isn’t in worse shape than BPC-157, but it isn’t clearly in better shape either, and the research record is shorter.

Honestly, this is a compound worth monitoring. If independent labs begin replicating the dopaminergic differentiation findings, the score changes. Right now, the mechanism promise earned it a real look; the evidence base hasn’t earned priority placement in an active research program. Worth knowing about. Not worth leading with.

Novelty

62

Mechanism promise

57

In-category differentiation

44

Evidence quality

22

Translational signal

18

Research bench value

50

Rationale The 9-position methylation creates a meaningfully distinct pharmacological profile from classic psychoactive beta-carbolines, with real dopaminergic neuroprotection and BDNF signal in rodent work. However, the published record is dominated by a tight cluster of German labs with no independent multi-lab replication and no human clinical data of any kind, pulling evidence and translational scores to the floor.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Beta-carboline alkaloid, dopaminergic neuroprotective small molecule (capsule format)

A 182 Da methylated beta-carboline alkaloid characterized for dopaminergic neuroprotective effects, increased dopamine neuron differentiation, and BDNF expression in animal models. Supplied as 30 capsules x 20 mg.

Abstract

9-Methyl-beta-carboline (9-Me-BC; CAS 2521-07-5; molecular formula C12H10N2; molecular weight 182.22) is a small-molecule beta-carboline alkaloid bearing a methyl substituent on the 9-position indole nitrogen. The compound is a member of the broader beta-carboline family, naturally occurring alkaloids found in trace concentrations in many plants (notably the harmal family of psychoactive plants used in traditional preparations) and present at low concentrations in mammalian tissues including human plasma. The synthetic 9-methylated variant has attracted research interest beginning in the 2010s for a distinctive pharmacological profile that combines dopaminergic neuroprotective effects, increased dopamine neuron differentiation in cell culture, and elevated BDNF expression in rodent brain. Unlike many psychoactive beta-carbolines (harmaline, harmine, others), 9-Me-BC has substantially reduced affinity for the monoamine oxidase A enzyme and substantially reduced psychoactive effects at the doses used in published preclinical work. The compound is supplied at Kodiac biolabs as a 30-capsule oral preparation, 20 milligrams per capsule, reflecting the small molecule’s stability and good oral bioavailability. There is no FDA-approved IND for 9-Me-BC in any indication. The principal limitations on the strength of the evidence are the relatively short duration of the published research record, dominance of a small number of laboratories (primarily in the German neuroscience research community), and the absence of human clinical data.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-015Open in new tab →

Download PDF →

Acquire 9-Me-BC from the catalog

View 9-Me-BC →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
SS-31

Plain-language summaryIntrigue 88 / 100

SS-31, also called elamipretide, is a four-amino-acid peptide that selectively targets the inner mitochondrial membrane. It binds cardiolipin (a unique mitochondrial lipid) and stabilizes the mitochondrial membrane during stress, with research interest in heart failure, kidney disease, and aging. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

63/100

Cardiolipin-targeted mitochondrial probe with real Phase 2/3 clinical data, mixed outcomes, and strong bench utility in mitochondrial disease models

Look, SS-31 is one of those compounds where the mechanism is genuinely beautiful and the clinical story is genuinely complicated. Hazel Szeto’s group at Cornell spent years establishing that cardiolipin, the signature phospholipid of the inner mitochondrial membrane, is a target you can actually modulate with a synthetic tetrapeptide. That insight wasn’t obvious when the SS series was first described. The Dmt substitution over tyrosine in SS-02 wasn’t cosmetic either: it’s what gives SS-31 the stability and binding affinity that makes it useful at all in biological systems, and mass spec distinguishes the two readily enough that adulteration is a tractable quality concern rather than an invisible one.

The mechanistic story is compelling at the bench level. Cardiolipin doesn’t just sit there in the inner membrane looking pretty; it scaffolds the supercomplexes of the electron transport chain, particularly the Complex I/III/IV associations. When you perturb that environment through oxidative stress, the supercomplexes destabilize, electron flow becomes leaky, ROS output increases, and you get the downstream cascade that defines mitochondrial dysfunction in aging and ischemic disease. SS-31 interrupts that cascade upstream, at the lipid level, rather than scavenging ROS after the fact. Thats mechanistically more interesting than antioxidant supplementation and it explains why the compound has stayed in serious investigator hands even as its clinical arc has been uneven.

The clinical translation is where the story gets messier. Stealth BioTherapeutics ran a genuine program: Phase 2 work in cardiac ischemia, heart failure with preserved ejection fraction, Barth syndrome, primary mitochondrial myopathies, and age-related macular degeneration. The AMD program hit a real wall; the FDA issued a complete response letter for geographic atrophy requesting additional data, and that’s a setback that can’t be soft-pedaled. But the Barth syndrome and primary mitochondrial myopathy results are legitimately interesting. Barth is a rare cardiolipin remodeling disorder where elamipretide’s mechanism isn’t just plausible, its almost mechanistically required. Phase 2 functional improvements in that population were meaningful. Primary mitochondrial myopathy data has been more modest but directionally real.

What we like: SS-31 remains a useful probe for cardiolipin biology at the bench. If you’re running oxidative stress models, aging models, or ischemia-reperfusion work, having SS-31 as a chemical tool lets you ask specifically whether cardiolipin stabilization is part of whatever protective phenotype you’re seeing. Thats real probe value that doesn’t depend on the clinical outcomes resolving cleanly.

What we don’t like: this peptide has been around since the early 2000s, the core mechanism literature is mature, and the Phase 3 record is mixed at best. SS-31 isn’t breaking new ground anymore; it’s validating or failing to validate an established idea in new disease contexts. For an investigator building a new research program from scratch, SS-31 is a well-characterized tool in an active space, not a frontier target. Solid mid-tier compound, genuinely important in its niche, not the first thing we’d prioritize for an undirected lab.

Novelty

55

Mechanism promise

72

In-category differentiation

65

Evidence quality

60

Translational signal

57

Research bench value

68

Rationale SS-31 earns its mid-tier placement on genuine mechanistic elegance (cardiolipin supercomplex stabilization upstream of ROS) and a real multi-indication clinical program through Stealth BioTherapeutics, but the compound’s 20-year vintage, an FDA complete response letter for geographic atrophy, and mixed Phase 3 signals pull novelty and translational scores down; bench value stays solid because it remains the reference peptide probe for cardiolipin biology and has no real structural analogue for that specific question.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic tetrapeptide mitochondrial-targeting cardiolipin-binding peptide

A 4-amino-acid mitochondrial-targeting peptide developed at Cornell University, characterized for binding to cardiolipin in the inner mitochondrial membrane and protecting mitochondrial function in oxidative stress.

Abstract

SS-31 (sequence D-Arg-Dmt-Lys-Phe-NH2, also known as elamipretide, Bendavia, MTP-131; CAS 736992-21-5; molecular formula C32H49N9O5; molecular weight 639.79) is a synthetic tetrapeptide developed in the laboratory of Hazel Szeto at Cornell University Medical College beginning in the early 2000s. The peptide is the most extensively characterized member of the Szeto-Schiller (SS) series of mitochondrial-targeting tetrapeptides. The biological mechanism is binding to cardiolipin in the inner mitochondrial membrane, which protects the membrane lipid environment from peroxidation, stabilizes the supercomplexes of the electron transport chain, and improves mitochondrial efficiency in conditions of oxidative stress or mitochondrial dysfunction. The compound is the active pharmaceutical ingredient in elamipretide (Bendavia), which has been advanced through Phase 2 and Phase 3 clinical trials by Stealth BioTherapeutics for primary mitochondrial myopathies, age-related macular degeneration (dry AMD with geographic atrophy), Barth syndrome, and other mitochondrial dysfunction indications. The clinical record is mixed; the most-promising results have come in Barth syndrome and primary mitochondrial myopathy. The compound is not approved by any regulatory authority for human or veterinary use as of this revision; recent FDA review in geographic atrophy resulted in a complete response letter requesting additional data. The Kodiac biolabs lot of record is SW260307, manufactured 7 March 2026 by Xian Sowu Biotech, with a vendor COA assay of 99.62 percent and a supplementary HPLC area-percent of 99.18 percent at 220 nm; both documents are archived on the lab results page.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-012Open in new tab →

Download PDF →

Acquire SS-31 from the catalog

View SS-31 →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
Dihexa

Plain-language summaryIntrigue 87 / 100

Dihexa is a small molecule based on a fragment of angiotensin (a blood pressure hormone). Despite that origin, what makes it interesting is what it does in the brain: research shows it dramatically increases the formation of new connections between brain cells (synapses), with potential applications in Alzheimer disease and cognitive enhancement. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundContested mechanism

52/100

Novel AT4 peptidomimetic with gutted evidence base after 2025 JPET retractions and failed clinical program

Look, the Dihexa story is one of the more spectacular collapses in recent CNS research, and it’s worth understanding what actually happened before deciding whether the compound has any remaining bench value.

The foundational papers, four JPET publications from the Harding lab at WSU between 2011 and 2014, were retracted in April 2025 following confirmed Western blot manipulation: band splicing and duplication across distinct experimental conditions. Those papers underwrote Athira Pharma, a $204 million IPO, and the clinical program that followed. The clinical lead, fosgonimeton (ATH-1017), failed to meet primary endpoints in both the LIFT-AD Phase 2/3 trial in mild-to-moderate Alzheimer disease and the SHAPE Phase 2 trial in dementia with Lewy bodies. A DOJ False Claims Act settlement landed in January 2025 for $4.07 million. The HGF/c-Met mechanism hypothesis that powered all of this is now scientifically untenable in its original form.

So what’s left? Honestly, more than nothing. Behavioral data from Morris water maze and novel object recognition paradigms that doesn’t depend on Western blot immunochemistry hasn’t been retracted. Electrophysiology work showing LTP facilitation in hippocampal slice preparations remains in the record. Synaptogenesis data from microscopy-based assays is similarly intact. These arent nothing: they suggest the compound does something pharmacologically active in the CNS, even if the original mechanistic story is gone.

The AT4 receptor / IRAP (insulin-regulated aminopeptidase) angle is the current best hypothesis for what Dihexa is actually doing. AT4-class pharmacology is genuinely understudied, and Dihexa’s profile as a small, orally active, BBB-penetrant peptidomimetic with picomolar activity in behavioral models is still unusual chemistry. There aren’t many compounds with those combined properties in this space, retracted mechanism or not. As an N-hexanoic-Tyr-Ile analog, it sits in a chemical class that has essentially no other well-characterized members at the CNS level.

We think the appropriate posture for bench investigators is to treat the HGF/c-Met story as dead, skip the Western blot replication attempts, and focus instead on what the compound does in electrophysiology and behavioral models relative to other AT4-class probes. The novelty and differentiation scores here are real: unusual chemistry, no close competitors in its niche. The evidence and translational scores are gutted because the clinical program failed and the core mechanistic papers are gone. That’s what a 52 looks like for a compound: genuinely interesting bench chemistry wrapped in a thoroughly compromised evidentiary record. Source it carefully, verify by HPLC, and treat the retracted literature as background context rather than foundation.

Novelty

70

Mechanism promise

50

In-category differentiation

70

Evidence quality

28

Translational signal

25

Research bench value

58

Rationale High novelty and differentiation scores survive intact because the compound’s AT4-derived peptidomimetic chemistry is genuinely unusual and uncontested; evidence and translational axes are severely depressed by the April 2025 JPET retractions of all four foundational HGF/c-Met papers and the failed fosgonimeton Phase 2/3 program, consistent with the spec’s explicit Dihexa callout targeting overall 52-58.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Angiotensin IV analog (procognitive small peptidomimetic)

A small angiotensin IV analog with a contested mechanism of action, a high-profile commercialization failure, and a literature record selectively retracted in 2025.

Abstract

Dihexa, also known as PNB-0408 and N-hexanoic-Tyr-Ile-(6) amino-hexanoic amide, is a hexapeptide-derived small molecule developed in the Harding laboratory at Washington State University as a procognitive analog of angiotensin IV. It was foundationally hypothesized to act through agonism of the hepatocyte growth factor (HGF) / c-Met receptor system, a mechanism that promised oral bioavailability, blood-brain barrier penetration at picomolar potency, and rapid synaptogenesis in cortical and hippocampal neurons. Between 2011 and 2014, four peer-reviewed publications established the compound’s commercial pipeline and underwrote the formation of Athira Pharma, a publicly traded biotechnology firm that raised over 204 million dollars in a 2020 initial public offering. Each of these four publications was retracted by the Journal of Pharmacology and Experimental Therapeutics in April 2025 following findings of academic misconduct, specifically the splicing and duplication of Western blot bands across distinct experimental conditions. The Department of Justice settled a False Claims Act qui tam action against Athira Pharma in January 2025 for 4.07 million dollars. The clinical lead derived from this program, fosgonimeton (ATH-1017, NDX-1017), failed to meet primary endpoints in the LIFT-AD Phase 2/3 trial in mild-to-moderate Alzheimer disease and the SHAPE Phase 2 trial in dementia with Lewy bodies. This monograph reviews what is now established about Dihexa’s chemistry, pharmacokinetics, behavioral effects, and clinical record, separating the verified record from the retracted, and provides sourcing, identity verification, reconstitution, and handling guidance for in vitro and in vivo investigative work.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-001Open in new tab →

Download PDF →

Acquire Dihexa from the catalog

View Dihexa →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026
5-Amino-1MQ

Plain-language summaryIntrigue 72 / 100

5-Amino-1MQ is a small molecule that selectively inhibits the NNMT enzyme. NNMT degrades NAD+ precursors and methyl donors; inhibiting it boosts cellular energy and fat metabolism, with research interest in obesity and metabolic disease. Capsule format here. Stocked in the Kodiac catalog as a research-only powder for laboratory work; not a medicine, not for human consumption.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

59/100

Novel NNMT inhibitor with elegant dual-node mechanism and solid preclinical case, human evidence still absent

Yeah, 5-Amino-1MQ is one of the more interesting small molecules to come out of academic medicinal chemistry in the last decade. The target, nicotinamide N-methyltransferase, had been a curiosity in cancer biology for years before anyone asked whether selective inhibition might be pharmacologically useful outside the oncology context. What changed is a pair of mechanistic insights that make NNMT genuinely interesting for metabolic and aging research: the enzyme simultaneously drains nicotinamide away from the NAD+ salvage pathway and consumes SAM, the universal methyl donor. Block NNMT and you potentially shift both the cellular NAD+ pool and methylation potential in the same direction. Thats the kind of elegant dual-node mechanism that gets bench scientists interested, and it’s distinct enough from standard NAD+ precursor supplementation to justify its own research program.

The evidence base is real but you have to be honest about what it consists of. Most of it is academic rodent work, primarily adipose and skeletal muscle stem cell models. The obesity model data from the Jacobson group and related labs is reasonably well-replicated at the preclinical level, with consistent effects on body composition, adipocyte size, and metabolic markers in diet-induced obesity models. The skeletal muscle stem cell aging angle is genuinely interesting and addresses a different biology than the adipose story. The trouble is there’s essentially no human data. No IND, no phase 1 safety signal to anchor on, no pharmacokinetic data in people to confirm that the rodent predictions hold under the real constraints of human metabolism.

What we like here is that 5-Amino-1MQ is the reference compound for NNMT biology full stop. If you’re studying this target in cancer, adipose, or aging contexts, this is the tool you reach for. There isn’t a cleaner or better-characterized selective inhibitor available for in vitro or in vivo work, which gives it real bench utility that extends beyond its own pharmacological story into any program touching NAD+ biology or one-carbon metabolism.

What we dont like is the evidence maturity problem. The research record is short, the human signal is absent, and there’s a real open question about how well the rodent adipose phenotype translates. The SAM depletion axis hasn’t been fully characterized for off-target methylation effects under prolonged dosing, and that gap matters when you’re talking about a compound that touches the universal methyl donor. Until there’s more replication across independent labs and some pharmacokinetic anchoring in humans, this stays in the promising preclinical bucket.

The score lands at 59 because the target and mechanism are genuinely novel, the preclinical case is credible, and the bench utility is real, but the translational gap is wide enough that you cant call it more than that. For investigators studying NAD+ biology, adipose metabolism, or muscle stem cell aging, 5-Amino-1MQ is probably already on your list. For everyone else, worth knowing about but premature to center a research program around.

Novelty

68

Mechanism promise

72

In-category differentiation

68

Evidence quality

38

Translational signal

38

Research bench value

60

Rationale Scores well on novelty and mechanism because NNMT inhibition with dual NAD+/SAM connectivity is a genuinely recent and elegant target, and 5-Amino-1MQ is the field reference compound; evidence quality and translational signal are pulled down significantly by the short research record and total absence of human pharmacokinetic or efficacy data.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Small-molecule selective NNMT inhibitor (capsule format)

A 159 Da quinolinium small molecule that selectively inhibits nicotinamide N-methyltransferase, characterized for effects on adipose metabolism and skeletal muscle stem cell function. Supplied as 60 capsules x 50 mg.

Abstract

5-Amino-1-methylquinolinium iodide (5-Amino-1MQ; CAS 954126-98-8; molecular formula C11H12N2; molecular weight 159.20 for the cation; the iodide salt has additional mass) is a small-molecule selective inhibitor of nicotinamide N-methyltransferase (NNMT, EC 2.1.1.1), the enzyme that methylates nicotinamide to N1-methylnicotinamide using S-adenosylmethionine (SAM) as the methyl donor. NNMT activity diverts nicotinamide away from the NAD+ salvage pathway and consumes SAM, which connects NNMT activity to both the cellular NAD+ pool and the methylation potential of the cell. NNMT is overexpressed in many cancers (where it has been characterized as an “oncometabolic” enzyme) and in obesity-associated white adipose tissue, where it has been linked to insulin resistance and to the metabolic dysfunction phenotype. Selective NNMT inhibitors including 5-Amino-1MQ have been developed primarily by academic medicinal chemistry groups beginning in the late 2010s and have been characterized in cell culture, in vivo rodent obesity and aging models, and in skeletal muscle stem cell and aging models. The compound is supplied at Kodiac biolabs as a 60-capsule oral preparation, 50 milligrams per capsule, reflecting the small molecule’s stability and oral bioavailability. There is no FDA-approved IND for 5-Amino-1MQ in any indication. The compound is not a regulated drug substance in the United States, the European Union, or Japan. The principal limitations on the strength of the evidence are the relatively short duration of the published research record and the limited human safety and efficacy data.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-014Open in new tab →

Download PDF →

Acquire 5-Amino-1MQ from the catalog

View 5-Amino-1MQ →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 8, 2026

←Previous Page

1 … 66 67 68 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.